JP Morgan Maintains Overweight on Eli Lilly, Lowers Price Target to $1100
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on Eli Lilly but lowers the price target from $1050 to $1100.
September 13, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Chris Schott maintains an Overweight rating on Eli Lilly, indicating continued confidence in the stock, but lowers the price target from $1050 to $1100, suggesting a more conservative outlook.
The Overweight rating suggests that JP Morgan still sees Eli Lilly as a strong investment, but the lowered price target indicates a slightly less optimistic view on its short-term price potential. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100